Shareholders of Israeli clinical-stage pharmaceutical company NeuroDerm voted to approve the proposed buyout by Mitsubishi Tanabe Pharma on September 12, the Japanese company said on the following day.Mitsubishi Tanabe announced in July that it would be acquiring NeuroDerm for roughly…
To read the full story
Related Article
- Mitsubishi Tanabe’s NeuroDerm Acquisition Completed
October 20, 2017
- (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 25, 2017
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





